See more : Profound Medical Corp. (PRN.TO) Income Statement Analysis – Financial Results
Complete financial analysis of Core One Labs Inc. (CLABF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Core One Labs Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Liberty Energy Inc. (LBRT) Income Statement Analysis – Financial Results
- KDDI Corporation (9433.T) Income Statement Analysis – Financial Results
- Amrutanjan Health Care Limited (AMRUTANJAN.BO) Income Statement Analysis – Financial Results
- Poxel S.A. (0RA2.L) Income Statement Analysis – Financial Results
- Duro Felguera, S.A. (MDF.MC) Income Statement Analysis – Financial Results
Core One Labs Inc. (CLABF)
About Core One Labs Inc.
Core One Labs Inc. operates as a biotechnology research and technology life sciences company. The company focuses on bringing psychedelic medicines to market through novel delivery systems, psychedelic assisted psychotherapy, and API grade psilocybin manufacturing. Its CannaStrips technology produces infused strips that allow for bioavailability of cannabis constituents. The company also offers consulting, financing, and micro cultivation services, as well as operates medical and wellness clinics. In addition, it provides natural health products; and news dissemination services. The company was formerly known as Lifestyle Delivery Systems Inc. and changed its name to Core One Labs Inc. in September 2019. Core One Labs Inc. was incorporated in 2010 and is headquartered in Vancouver, Canada.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 458.54K | 431.62K | 0.00 | 5.04M | 4.08M | 191.13K | 56.09K | 58.30K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 42.20K | 38.77K | 0.00 | 5.71M | 5.77M | 0.00 | 0.00 | 1.60K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 416.34K | 392.85K | 0.00 | -669.57K | -1.69M | 191.13K | 56.09K | 56.70K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 90.80% | 91.02% | 0.00% | -13.28% | -41.40% | 100.00% | 100.00% | 97.26% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 80.34K | 627.29K | 97.91K | 1.12M | 1.12M | 2.71M | 65.08K | 59.06K | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 8.36M | 5.47M | 8.13M | 7.77M | 8.67M | 1.63M | 920.79K | 304.70K | 328.25K | 459.34K | 260.27K |
| Selling & Marketing | 0.00 | 3.71M | 1.03M | 1.42M | 1.29M | 1.78M | 112.87K | 8.77K | 15.00K | 0.00 | 0.00 | 0.00 |
| SG&A | 8.17M | 12.07M | 6.50M | 9.56M | 9.06M | 10.44M | 1.74M | 929.56K | 319.70K | 328.25K | 459.34K | 260.27K |
| Other Expenses | 0.00 | 37.30K | 614.95K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.25M | 12.64M | 7.14M | 14.67M | 10.24M | 13.16M | 2.00M | 1.11M | 430.17K | 328.25K | 459.34K | 260.27K |
| Cost & Expenses | 8.30M | 12.64M | 7.14M | 20.38M | 16.01M | 13.16M | 2.00M | 1.11M | 430.17K | 328.25K | 459.34K | 260.27K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 4.34K | 12.65K | 0.00 | 752.00 | 2.07K | 2.57K | 109.00 | 51.00 |
| Interest Expense | 1.37K | 22.25K | 16.47K | 575.41K | 130.29K | 32.65K | 0.00 | 20.01K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 42.20K | 38.77K | 206.30K | 6.09M | 54.74K | 6.92K | 187.56K | 121.51K | 110.47K | 279.94K | 0.00 | 0.00 |
| EBITDA | -7.80M | -12.13M | -6.52M | -9.25M | -11.87M | -12.97M | -1.75M | -931.17K | -319.70K | -212.13K | -459.34K | -260.27K |
| EBITDA Ratio | -1,699.99% | -2,811.50% | 0.00% | -183.52% | -290.79% | -6,786.39% | -3,125.56% | -1,597.26% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -7.84M | -12.17M | -6.52M | -15.34M | -11.92M | -12.98M | -1.94M | -1.07M | -430.17K | -492.07K | -459.34K | -260.27K |
| Operating Income Ratio | -1,709.20% | -2,820.48% | 0.00% | -304.24% | -292.13% | -6,790.01% | -3,459.98% | -1,841.30% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -8.14M | -24.82M | -39.75M | -5.74M | -1.10M | -154.02K | -925.78K | -133.99K | 2.07K | -116.12K | 109.00 | 0.00 |
| Income Before Tax | -15.98M | -37.05M | -46.90M | -21.65M | -13.15M | -13.16M | -2.87M | -1.21M | -428.10K | -441.80K | -459.23K | 0.00 |
| Income Before Tax Ratio | -3,485.36% | -8,585.16% | 0.00% | -429.47% | -322.33% | -6,887.69% | -5,110.62% | -2,069.84% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 3.00 | 59.55K | 7.71M | 386.16K | -736.22K | -535.24K | 0.00 | 20.01K | 0.00 | -166.39K | 0.00 | 260.22K |
| Net Income | -15.98M | -37.05M | -54.62M | -21.46M | -12.29M | -12.60M | -2.87M | -1.21M | -428.10K | -441.80K | -459.23K | -260.22K |
| Net Income Ratio | -3,485.36% | -8,585.16% | 0.00% | -425.72% | -301.09% | -6,590.56% | -5,110.62% | -2,069.84% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.49 | -2.57 | -10.27 | -15.25 | -10.56 | -17.52 | -8.71 | -7.79 | -12.06 | -14.11 | -14.76 | -10.65 |
| EPS Diluted | -0.49 | -2.57 | -10.27 | -15.25 | -10.56 | -17.52 | -8.71 | -7.79 | -12.06 | -14.11 | -14.76 | -10.65 |
| Weighted Avg Shares Out | 32.71M | 14.42M | 5.32M | 1.41M | 1.16M | 718.83K | 328.95K | 154.82K | 35.50K | 31.32K | 31.11K | 24.42K |
| Weighted Avg Shares Out (Dil) | 32.71M | 14.42M | 5.32M | 1.41M | 1.16M | 718.83K | 328.95K | 154.82K | 35.50K | 31.32K | 31.11K | 24.42K |
Core One Enters into Loan Agreement with Right Season Investments
VANCOUVER, BC / ACCESSWIRE / July 8, 2024 / Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6, WKN: A3CSSU) (the "Company" or "Core One"), is pleased to announce that it has entered into a loan agreement (the "Loan Agreement") with Right Season Investments...
Core One Labs Inc. Announces Initial Agreement for Potential Sale of Proprietary Biosynthetic Psilocybin, Facilitating Entry into the International Market
VANCOUVER, BC / ACCESSWIRE / December 8, 2023 / Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6) (WKN:A3CSSU) (the "Company" or "Core One") is pleased to announce the signing of an Initial Agreement (the "Agreement") with Cube Psytech Corp. ("Cube Psytech") marking a...
Core One Labs' Akome Reveals Impressive Results for its Psychedelic Bio-Compounds Designed to Target Alzheimer's and Parkinson's, Showing Potential to Outperform Current Treatment Methods
VANCOUVER, BC / ACCESSWIRE / December 1, 2023 / Core One Labs Inc. ("Core One" or the "Company") (CNSX:COOL)(OTCQB:CLABF)(Frankfurt:LD6) (WKN: A3CSSU), an emerging leader in the field of neuroscience and psychedelics, is delighted to share the exciting results of its...
Core One's Akome Reveals Groundbreaking Positive Results from its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer's and Parkinson's Disease
VANCOUVER, BC / ACCESSWIRE / August 4, 2023 / Core One Labs Inc. (CSE:COOL) (OTCQB:CLABF) (Frankfurt:LD6, WKN:A3CSSU), (the "Company" or "Core One") is delighted to announce the receipt of additional positive results from its second round ("Round 2") of Stage...
Core One Labs', Awakened Biosciences, Announces Groundbreaking Step Forward in Isolating and Purifying Psilocybin from Mushroom Biomass
Core One's Wholly-Owned Subsidiary has filed a patent application with the United States Patent and Trademark Office VANCOUVER, BC / ACCESSWIRE / August 1, 2023 / Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6, WKN:A3CSSU) (the "Company" or "Core One") proudly announces a...
Core One's Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer's and Parkinson's Disease
VANCOUVER, BC / ACCESSWIRE / July 28, 2023 / Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6) (WKN:A3CSSU) (the "Company" or "Core One"), is excited to share positive results from its first round of Stage 1 animal model studies ("Round 1"), conducted by...
Core One Labs Enters into Letter of Intent for First Sale of Its Psychedelic Compounds
VANCOUVER, BC / ACCESSWIRE / July 21, 2023 / Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6) (WKN: A3CSSU) (the "Company" or "Core One") is pleased to announce that its wholly-owned subsidiary, GMP Drug Inc. ("GMP Drug"), has entered into a non-binding letter...
Core One's Vocan Biotechnologies Incorporates New Bioreactor Equipment into Production Process Significantly Increasing Throughput of Proprietary Biosynthetic Psilocybin
VANCOUVER, BC / ACCESSWIRE / July 11, 2023 / Core One Labs Inc. (CSE:COOL), (OTCQB:CLABF), (Frankfurt:LD6, WKN:A3CSSU) (the "Company") is pleased to announce that its wholly-owned subsidiary Vocan Biotechnologies Inc. ("Vocan") has incorporated a state-of-the-art, high density, fermenting and bio-processing...
Core One's Vocan Files International Patent for its Breakthrough Proprietary Biosynthetic Psilocybin Production Method
VANCOUVER, BC / ACCESSWIRE / July 7, 2023 / Core One Labs Inc. (CSE:COOL), (OTCQB:CLABF), (Frankfurt:LD6), (WKN: A3CSSU) (the "Company" or "Core One") is pleased to announce that its wholly owned subsidiary, Vocan Biotechnologies Inc. ("Vocan"), has completed final steps...
Core One Labs to Host Special Investor Webcast on Tuesday, January 18, 2022
VANCOUVER, British Columbia, Jan. 15, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”) is pleased to announce, as a follow up to the press release dated January...
Source: https://incomestatements.info
Category: Stock Reports